Gerald Lawrence is the firm’s Chief Operating Officer and a shareholder, based in Lowey’s West Conshohocken, Pennsylvania office. Mr. Lawrence has been consistently recognized by Super Lawyers as one of Pennsylvania’s leading litigation attorneys, including selection to Pennsylvania Super Lawyers each year from 2005 through 2025, with multiple Top 100 statewide and Philadelphia rankings. He also holds the AV Preeminent Peer Rating, the highest rating for legal ability and ethics, from Martindale Hubbell. In addition, Mr. Lawrence has proudly served the Commonwealth of Pennsylvania as a member of the Pennsylvania Judicial Advisory Commission (4 Pa. Code § 7.845) for several terms and currently by appointment of Governor Shapiro. He has served as Chair of the Pennsylvania Board of Law Examiners, Vice-Chairman of the Disciplinary Board of the Supreme Court of Pennsylvania, and a member of the Supreme Court of Pennsylvania Investment Advisory Board. Mr. Lawrence served over twenty years as Commissioner of the Board of Elections in Delaware County Pennsylvania, including as Chairman. He twice served the United States as a member of Presidential Electoral College.

He has enjoyed success in many cases. Mr. Lawrence has represented health benefits plan providers and recovered billions of dollars on their behalf, including in In Re National Prescription Opioid Litigation MDL No. 2804 (N.D. Ohio 2017) (Counsel for 47 private health plans), In Re Purdue Pharma LP, Case No. 19-23649 (SHL) (S.D.N.Y.) (negotiated $389 million recovery Third Party Payor health Plans), In Re Ranbaxy Generic Drug Application Antitrust Litigation, MDL No. 2878, (D. Mass. 2022) (lead class counsel and negotiated $145 million settlement for health plans after defendant manipulated the FDA’s generic-drug approval process); Blue Cross Blue Shield Association v. GlaxoSmithKline, 417 F. Supp. 3d 531 (E.D. Pa. 2019); Aetna v. Insys Therapeutics, No. 17-cv-4812, 330 F.R.D. 427 (E.D. Pa. 2019); In re Lidoderm Antitrust Litigation, MDL No. 2521, 2018 WL 4620695 (N.D. Cal. Sept. 20, 2018) (lead negotiator for independently settling health plans in $105 million settlement with 3 defendants); Aetna v. Insys Therapeutics, 324 F. Supp. 3d 541 (E.D. Pa. 2018); In re Aggrenox Antitrust Litigation, 94 F. Supp. 3d 224 (D. Conn 2015); In re Lidoderm Antitrust Litigation 103 F.Supp.3d 1155 (N.D. Cal. 2015); In re: Skelaxin (Metaxalone) Antitrust Litigation, Case No. 12-md-02343, MDL No. 2343 (D. Tenn.) (Third Party Payor allocation counsel), Blue Cross & Blue Shield Association v. SmithKlineBeecham Corp., Phila. C.C.P., August Term 2012, No. 997 (Flonase opt-out settlement), New England Carpenters Health Benefit Fund, et al. v. First DataBank, Inc. and McKesson Corp., No. 05-cv- 11148 (D. Mass.) (TPP allocation counsel for $285 million TPP share of $350 million settlement), Medical Mutual of Ohio v. Merck & Co., Inc., N.J. Superior Ct. (Atlantic County), Docket No. ATL-L-07319-06-MT, Case No. 619 ($65 million Vioxx settlement), In re Actiq Sales and Marketing Practices Litigation, 790 F. Supp. 2d 313 (E.D. Pa. 2011), Inre Pharmaceutical Industry Average Wholesale Price Litigation, No. 01-CV-12257, MDL No. 1456 (D. Mass.) (ISHP counsel for opt-out TPPs), Humana, Inc. v. GlaxoSmithKline, Phila. C.C.P., December Term 2004, No. 3140 (Augmentin opt-out settlement), In re: Cardizem CD Antitrust Litig., 218 F.R.D. 508 (E.D. Mich. 2003) ($80 million settlement). He represented Aetna in In re Neurontin Marketing & Sales Practices Litigation, 712 F.3d 51 (1st Cir. 2013) (holding drug manufacturers accountable to health insurers for damages attributable to marketing fraud), and as the representative of a certified class in In re Wellbutrin XL Antitrust Litig., 756 F. Supp. 2d 670 (E.D. Pa. 2010) (the first decision to allow class action prosecution of antitrust claims under New York law).

Mr. Lawrence was part of the Lowey team that represented the Treasurer of the Commonwealth of Pennsylvania in In re GSE Bonds Antitrust Litigation, 19-cv-1704 (S.D.N.Y. 2020), resulting in five settlements which recovered $386.5 million from the sixteen largest GSE bond dealers which had conspired to inflate the prices at which newly-issued GSE Bonds were sold to investors in the secondary market.

Mr. Lawrence’s pro bono work includes significant and important cases. He argued to overturn the Pennsylvania Defense of Marriage Act while representing a public official before the Pennsylvania Supreme Court appealing an order enjoining him from issuing marriage licenses to same sex couples. Pennsylvania v. Hanes, 77 MAP 2013 (Pa.). Mr. Lawrence is a graduate of Georgetown University (B.S., B.A. 1990) and the Villanova University School of Law (J.D. 1993).

Mr. Lawrence is admitted to practice law in the Commonwealth of Pennsylvania and State of New York; and in the U.S. Courts of Appeals for the 1st, 2nd and 3rd Circuits and the U.S. District Courts for the Eastern and Middle Districts of Pennsylvania and the Eastern and Southern Districts of New York.